The impact of left ventricular hypertrophy on survival in candidates for liver transplantation
- PMID: 24659368
- PMCID: PMC4342997
- DOI: 10.1002/lt.23875
The impact of left ventricular hypertrophy on survival in candidates for liver transplantation
Abstract
Left ventricular hypertrophy (LVH) occurs in 12% to 30% of patients with cirrhosis; however, its prognostic significance is not well studied. We assessed the association of LVH with survival in patients undergoing a liver transplantation (LT) evaluation. We performed a multicenter cohort study of patients undergoing an evaluation for LT. LVH was defined with transthoracic echocardiography. The outcome of interest was all-cause mortality. LVH was present in 138 of 485 patients (28%). Patients with LVH were older, more likely to be male and African American, and were more likely to have hypertension. Three hundred forty-five patients did not undergo transplantation (212 declined, and 133 were waiting): 36 of 110 patients with LVH (33%) died, whereas 57 of 235 patients without LVH (24%) died (P = 0.23). After LT, 8 of 28 patients with LVH (29%) died over the course of 3 years, whereas 9 of 112 patients without LVH (8%) died (P = 0.007). This finding was independent of conventional risk factors for LVH, and all deaths for patients with LVH occurred within 9 months of LT. No clinical or demographic characteristics were associated with mortality among LVH patients. In conclusion, the presence of LVH is associated with an early increase in mortality after LT, and this is independent of conventional risk factors for LVH. Further studies are needed to confirm these findings and identify factors associated with mortality after transplantation to improve outcomes.
© 2014 American Association for the Study of Liver Diseases.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures
References
-
- De Marco M, Chinali M, Romano C, Benincasa M, D'Addeo G, D'Agostino L, de Simone G. Increased left ventricular mass in pre-liver transplantation cirrhotic patients. J Cardiovasc Med (Hagerstown) 2008;9:142–146. - PubMed
-
- Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM, Cabrera-Muñoz ML, Méndez-Navarro J, Morán-Villota S, Dehesa-Violante M. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol. 2011;10:321–326. - PubMed
-
- Inserte J, Perelló A, Agulló L, Ruiz-Meana M, Schlüter KD, Escalona N, et al. Left ventricular hypertrophy in rats with biliary cirrhosis. Hepatology. 2003;38:589–598. - PubMed
-
- Liu H, Lee SS. Nuclear factor-κB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int. 2008;28:640–648. - PubMed
-
- Møller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol. 2013;167:1101–1108. - PubMed
Publication types
MeSH terms
Grants and funding
- RR00585/RR/NCRR NIH HHS/United States
- M01 RR000585/RR/NCRR NIH HHS/United States
- RR00645/RR/NCRR NIH HHS/United States
- R01 HL113988/HL/NHLBI NIH HHS/United States
- DK064103/DK/NIDDK NIH HHS/United States
- RR00046/RR/NCRR NIH HHS/United States
- M01 RR000645/RR/NCRR NIH HHS/United States
- M01 RR000046/RR/NCRR NIH HHS/United States
- DK065958/DK/NIDDK NIH HHS/United States
- R03 DK065958/DK/NIDDK NIH HHS/United States
- M01 RR000032/RR/NCRR NIH HHS/United States
- R03 DK064103/DK/NIDDK NIH HHS/United States
- K24 HL103844/HL/NHLBI NIH HHS/United States
- RR00032/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical